C07D 317/60
Radicals substituted by carbon atoms having three bonds to hetero atoms with
Official title: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D317/60 (Radicals substituted by carbon atoms having three bonds to hetero atoms with) appears on 502 US grants and 350 published applications in this corpus.
Search patents in C07D- Granted patents
- 502
- Published applications
- 350
- Assignees
- 275
- Inventors
- 1,642
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 17 | 0 |
| 1977 | 10 | 0 |
| 1978 | 6 | 0 |
| 1979 | 8 | 0 |
| 1980 | 14 | 0 |
| 1981 | 9 | 0 |
| 1982 | 8 | 0 |
| 1983 | 3 | 0 |
| 1984 | 3 | 0 |
| 1985 | 7 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 4 | 0 |
| 1989 | 4 | 0 |
| 1990 | 9 | 0 |
| 1991 | 8 | 0 |
| 1992 | 3 | 0 |
| 1993 | 9 | 0 |
| 1994 | 12 | 0 |
| 1995 | 6 | 0 |
| 1996 | 10 | 0 |
| 1997 | 17 | 0 |
| 1998 | 23 | 0 |
| 1999 | 13 | 0 |
| 2000 | 21 | 0 |
| 2001 | 21 | 2 |
| 2002 | 20 | 14 |
| 2003 | 11 | 25 |
| 2004 | 14 | 31 |
| 2005 | 8 | 14 |
| 2006 | 13 | 19 |
| 2007 | 10 | 21 |
| 2008 | 11 | 17 |
| 2009 | 16 | 17 |
| 2010 | 18 | 27 |
| 2011 | 12 | 21 |
| 2012 | 16 | 11 |
| 2013 | 15 | 15 |
| 2014 | 15 | 18 |
| 2015 | 12 | 16 |
| 2016 | 10 | 9 |
| 2017 | 6 | 9 |
| 2018 | 9 | 8 |
| 2019 | 9 | 9 |
| 2020 | 6 | 7 |
| 2021 | 3 | 5 |
| 2022 | 6 | 6 |
| 2023 | 3 | 8 |
| 2024 | 3 | 10 |
| 2025 | 6 | 5 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and N-methyl-1,3-benzodioxolylbutanamine (MBDB)14 Jul 2026US 12,679,817 B2Pharmala Biotech Inc.
- Short-acting monoamine releasers31 Mar 2026US 12,590,077 B2Solvonics Therapeutics Ireland Holdings Limited
- Substituted ethylamine fused heterocyclic mescaline derivatives9 Dec 2025US 12,492,179 B2Enveric Biosciences Canada Inc.
- Compounds advantageous in the treatment of central nervous system diseases and disorders2 Dec 2025US 12,486,218 B2Aurimmed Pharma, Inc.
- Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-g]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol25 Nov 2025US 12,479,801 B2H. Lundbeck A.S.
- Process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol23 Jul 2026US 2026/0209181 A1H. Lundbeck A.S.
- Noncovalent Keap1-Nrf2 Small-Molecule Inhibitors9 Jul 2026US 2026/0193170 A1University of Copenhagen
- Covalent, chemogenetic activators for k2p potassium channels and uses thereof9 Apr 2026US 2026/0098008 A1The Regents of the University of California
- Substituted n-propylamine fused heterocyclic mescaline derivatives19 Mar 2026US 2026/0078102 A1Enveric Biosciences Canada Inc.
- Substituted ethylamine fused heterocyclic mescaline derivatives5 Mar 2026US 2026/0062399 A1Enveric Biosciences Canada Inc.
Most cited
By later US patents
- Condensed heterocyclic compounds154US 5,037,825 AHoffmann-La Roche Inc. · 1991
- Immunotherapeutic agents153US 5,929,117 ACelgene Corporation · 1999
- Modulators of ATP-binding cassette transporters117US 7,691,902 B2Vertex Pharmaceuticals Incorporated · 2010
- Immunosuppressive compounds109US 5,192,773 AVertex Pharmaceuticals Incorporated · 1993
- Immunosuppressive compounds94US 5,330,993 AVertex Pharmaceuticals Incorporated · 1994